FDA OKs Zolbetuximab for Gastric, Gastroesophageal Cancer

Views: 4424

The US Food and Drug Administration (FDA) has approved zolbetuximab (Vyloy, Astellas Pharma) in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma that is claudin 18.2 positive.  FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay…
Read More